Follow RSS for latest reports on this topicPatisiran (ALN-TTR02) - Market Research and Reports

Patisiran, a second-generation siRNA therapy that targets the transthyretin (TTR) gene, for the treatment of TTR-mediated amyloidosis (ATTR).  Patisiran comprises siRNA molecules encapsulated in lipid nanoparticles, using Tekmira Pharmaceuticals’ lipid nanoparticle technology, to enable delivery into the cell.

TTR is a soluble transport protein. Mutations in the TTR gene, which is predominantly expressed in the liver, cause TTR to form abnormal insoluble amyloid proteins which accumulate and damage organs and tissue, mainly the heart or nerves. The condition is referred to as familial amyloid polyneuropathy (FAP) when peripheral nerves are primarily affected, and familial amyloid cardiomyopathy (FAC) in the case of cardiac presentations.

For further details - http://investors.alnylam.com/releasedetail.cfm?ReleaseID=805999

Adapted from - Thomson Reuters Cortellis Competitive Intelligence

BioPortfolio's Easy Ordering System

  1. Search for the report you need from our store
  2. Make online payment with our easy checkout process
  3. Receive PDF report via email

Easy Online Payment or Pro Forma Invoice

We accept the following credit cards...



or can supply a pro-forma invoice if required.

Related Reports:

Additional Searches

You may also like to search separately for: Patisiran (ALN-TTR02)

We Stock...

  • Allied Market Research
  • CBR Pharma
  • Current Partnering
  • Firstword
  • Global Data
  • Global Markets Direct
  • ICD Research
  • Infinti Research Technavio
  • Marketline
  • Markets and Markets
  • Micro Markets Monitor
  • MP Advisors
  • Venture Planning Group
  • GMR Data
{STICKYFOOTERMOBILE}